David L. Rimm

Oncology · 2000–2021

A researcher in the Science corpus: 16 papers; trusts 1 researcher and is trusted by 4 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 150 citations into it; #613 of 1,698 by trust here, #409 by citations
• Molecular Biology — 42 citations into it; #8,660 of 17,773 by trust here, #5,705 by citations

Whom David L. Rimm trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Pierre Legendre
2. R. Camp

Who trusts David L. Rimm overall

1. R. Camp
2. E. Glory

Papers from David L. Rimm's perspective

Ordered by how strongly the researchers David L. Rimm trusts endorse each paper. Same corpus, a different order for every researcher.

1. Species associations: the Kendall coefficient of concordance revisited
2. Validation of Tissue Microarray Technology in Breast Carcinoma (Laboratory Investigation)
3. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Archives of Pathology & Laboratory Medicine)
4. Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. (Science)
5. Nuclear localization of EGF receptor and its potential new role as a transcription factor (Nature Cell Biology)
6. Clinical prediction rules. Applications and methodological standards.
7. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (New England Journal of Medicine)
8. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. (American Journal of Pathology)
9. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (Science)
10. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to… (Journal of Clinical Oncology)

Their papers

• Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma (2005) — 1,567 citations
• Automated subcellular localization and quantification of protein expression in tissue microarrays (2002) — 773 citations
• Validation of Tissue Microarray Technology in Breast Carcinoma (2000) — 843 citations
• A proposal for validation of antibodies (2016) — 562 citations
• X-Tile (2004) — 1,990 citations
• PD-L1 as a biomarker of response to immune-checkpoint inhibitors (2021) — 1,271 citations
• Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. (2020) — 1,200 citations
• Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group (2020) — 663 citations
• Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology (2019) — 1,383 citations
• A Prospective, Multi-Institutional Assessment of Four Assays for PD-L1 Expression in NSCLC by Immunohistochemistry (2017) — 718 citations
• Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer (2017) — 656 citations
• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. (2015) — 2,798 citations
• Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab (2014)
• Programmed death ligand-1 expression in non-small cell lung cancer (2013) — 753 citations
• Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features (2009) — 1,423 citations
• Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. (2006) — 858 citations